Clinical Trial Update: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) [Phase 2]

View source ↗

Summary

A pediatric MATCH phase 2 trial assessed olaparib in children with relapsed or refractory advanced solid tumors or non-Hodgkin lymphoma carrying DNA damage repa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Low-grade Glioma
• Malignant Glioma
• Medulloblastoma
• Neuroblastoma
• Non-hodgkin Lymphoma
• Osteosarcoma
• Wilms Tumor

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-04-25